Skip to main content

Non-Small Cell Lung Cancer

Our upcoming investigations represent a significant breakthrough in non-small cell lung cancer research, offering promise for individuals living with this condition.

Non-Small Cell Lung Cancer Research & Clinical Trials

Lung cancer remains one of the most challenging diseases to treat, with advanced or metastatic NSCLC presenting particularly complex management scenarios. We are conducting a clinical trial at Hightower Clinical to evaluate a novel approach to treating previously untreated advanced or metastatic NSCLC.

The study aims to enroll patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) who meet specific eligibility criteria. After a comprehensive screening phase, enrolled subjects will receive the study drug in combination or alone for an average of 18 hours daily. Treatment will continue for 24 months or until specified criteria are met, with rigorous monitoring and follow-up throughout the study duration.


Non-Small Cell Lung Cancer

Current Status




Frequently Asked Questions

How do I enroll in the PROACT LUNG study?

Eligible participants must provide informed consent and complete the necessary enrollment procedures outlined by the study protocol. The study coordinator or research team will assist you through the enrollment process.

What happens if I discontinue study treatment?

If study treatment is discontinued for reasons other than disease progression, participants will be monitored for disease status until confirmed progression, initiation of non-study cancer treatment, withdrawal of consent, or loss to follow-up. Monthly follow-ups will be conducted after treatment until the end of the study.

How long will the study last?

Participants will be followed for approximately 2 years from the time of signing the Informed Consent Form (ICF) through the final contract, with treatment continuing for 24 months or until specified criteria are met.